Elizabeth L. Lockerman

Molecular Mechanisms of Resistance to First- and Second-Generation ALK Inhibitors in <i>ALK</i> -Rearranged Lung Cancer

Justin F. Gainor, Leila Dardaei, Satoshi Yoda et al. · Cancer Discovery · 2016 · 1.1K citations · Full text

Medicine, Oncology, Pharmacology +10

Tumor cells can follow distinct evolutionary paths to become resistant to epidermal growth factor receptor inhibition

Aaron N. Hata, Matthew J. Niederst, Hannah L. Archibald et al. · Nature Medicine · 2016 · 999 citations · Full text

Medicine, Cancer Biology, Oncology +15

The ALK Inhibitor Ceritinib Overcomes Crizotinib Resistance in Non–Small Cell Lung Cancer

Luc Friboulet, Nanxin Li, Ryohei Katayama et al. · Cancer Discovery · 2014 · 842 citations · Full text

Medicine, Oncology, Pharmacology +15

Patient-derived models of acquired resistance can identify effective drug combinations for cancer

Adam Crystal, Alice T. Shaw, Lecia V. Sequist et al. · Science · 2014 · 733 citations

Medicine, Oncology, Pharmacology +17

RB loss in resistant EGFR mutant lung adenocarcinomas that transform to small-cell lung cancer

Matthew J. Niederst, Lecia V. Sequist, John T. Poirier et al. · Nature Communications · 2015 · 633 citations · Full text

Medicine, Cancer Biology, Oncology +17